TITLE

Quality of Life and Functional Results of Submucosal Injection Therapy Using Dextranomer Hyaluronic Acid for Fecal Incontinence

AUTHOR(S)
Schwandner, Oliver; Brunner, Marion; Dietl, Otto
PUB. DATE
June 2011
SOURCE
Surgical Innovation;Jun2011, Vol. 18 Issue 2, p130
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aim: The aim of this prospective study was to analyze safety and functional outcome of transanal submucosal injection of dextranomer hyaluronic acid (“bulking agents therapy”) in patients with passive fecal incontinence. Methods: All patients who underwent transanal injection therapy were prospectively enrolled in this study. Inclusion criteria included fecal incontinence (internal anal sphincter dysfunction) after failed conservative treatment. The procedure was performed in a standardized technique, including submucosal injection of 4 × 1 mL dextranomer hyaluronic acid 5 mm above the dentate line. The primary endpoint focused on symptom improvement provided as the change in incontinence status and quality of life using validated scores (Wexner incontinence score, symptom-specific Fecal Incontinence Quality of Life [FIQoL] scale, and generic EQ-5D-Visual Analogue Scale [EQ-5D-VAS]). Results: Within the observation period (July 2007 to May 2009), a total of 21 patients (17 women) with passive fecal incontinence were treated. Neither morbidity nor adverse events were documented. Three months postoperatively, 61.1% (11/18) showed significant improvement of symptoms (reduction of incontinence episodes and soiling), which was sustained after 20 months in 55.6% (10/18). Wexner incontinence score decreased from 16.8 to 12.3 (P > .05). Significant improvement was documented for FIQoL and EQ-5D-VAS (P < .05). Conclusion: The current results indicate that injection therapy using hyaluronic acid is an innovative and minimally invasive procedure with no morbidity. Although Wexner incontinence score is not significantly influenced, a significant improvement in quality of life was observed in more than 50% of patients.
ACCESSION #
62030143

 

Related Articles

  • Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents. Danielson, J.; Karlbom, U.; Wester, T.; Graf, W. // Techniques in Coloproctology;Aug2013, Vol. 17 Issue 4, p389 

    Background: Stabilized non-animal hyaluronic acid/dextranomer (NASHA Dx) gel as injectable bulking therapy has been shown to decrease symptoms of faecal incontinence, but the durability of treatment and effects and influence on quality of life (QoL) is not known. The aim of this study was to...

  • Treatment of faecal incontinence: current and emerging therapies. Schwandner, Oliver // British Journal of Neuroscience Nursing;Aug2012, Vol. 8 Issue 4, p170 

    This article reviews current and emerging treatments for faecal incontinence (FI), focusing in particular on the innovative use of submucosal injection of dextranomer hyaluronic acid as a bulking agent. FI is a common condition that affects up to 21% of adults, and its severity increases with...

  • Dextranomer in Stabilized Sodium Hyaluronate (Solesta®) In Adults with Faecal Incontinence. Hoy, Sheridan M. // Drugs;2012, Vol. 72 Issue 12, p1671 

    Dextranomer in stabilized sodium hyaluronate, hereafter referred to as dextranomer/hyaluronic acid, is a biocompatible bulking agent administered by submucosal injection. It is hypothesized to expand the submucosal layer of the proximal anal canal, thereby augmenting bowel control. Treatment...

  • Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid-our experience. Mylarappa, Prasad; Puvvada Sandeep, Prathvi; Banale, Kailash B.; Ramesh, D. // Al Ameen Journal of Medical Sciences;Jul-Sep2013, Vol. 6 Issue 3, p260 

    Objectives: We report our experience with subureteral submucosal injection therapy for vesicoureteral reflux and determine the safety and efficacy in patients treated with dextranomer/ hyaluronic acid co-polymer. Background: Vesicoureteral reflux affects 1% of children and increases the chances...

  • Clinical shorts. Kelsall, Diane // CMAJ: Canadian Medical Association Journal;5/17/2011, Vol. 183 Issue 8, p933 

    The article focuses on several clinical medicine studies. It mentions the CRASH-2 multicountry randomized trial which showed that early treatment with tranexamic acid greatly reduces the risk of death due to bleeding after a trauma. It presents a sham-controlled trial which revealed that anal...

  • Endoscopic treatment of vesicoureteral reflux in children with subureteral dextranomer/hyaluronic acid injection: a single-centre, 7-year experience. Biočić, Mihovil; Todorić, Jakov; Budimir, Dražen; Cvitković Roić, Andrea; Pogorelić, Zenon; Jurić, Ivo; Šušnjar, Tomislav // Canadian Journal of Surgery;Oct2012, Vol. 55 Issue 5, p301 

    Background: The goals of medical intervention in patients with vesicoureteral reflux are to allow normal renal growth, prevent infections and pyelonephritis, and prevent renal failure. We present our experience with endoscopic treatment of vesicoureteral reflux in children by subureteral...

  • Dextranomer/hyaluronic acid.  // Reactions Weekly;3/7/2009, Issue 1242, p20 

    The article describes the case of a woman who developed an obstructive suburethral mass following periurethral injection of dextranomer/hyaluronic acid for treatment of mild pure urinary stress incontinence. Two years after taking periurethral injections of dextranomer/hyaluronic acid, she...

  • How to perform a modified STING procedure for reflux. Kirsch, Andrew J.; Andriole, Gerald L. // Urology Times;Aug2004, Vol. 32 Issue 11, p22 

    Describes a modified subureteric transurethral injection (STING) procedure for treatment of vesicoureteral reflux (VUR). Details of the STING technique using dextranomer and hyaluronic acid copolymer implant injection; Maximization of ureteral coaptation; Patient preparation.

  • Dextranomer/hyaluronic acid.  // Reactions Weekly;May2014, Vol. 1502 Issue 1, p15 

    An abstract of the article "Late ureteral obstruction after injection of dextranomer/hyaluronic acid copolymer," by S. Christen and colleagues is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics